Friday, October 2, 2026

Kim Jong Un and Russia’s Top Security Chief Just Had a Private Chat

Kim Jong Un met with Russia's Sergei Shoigu to discuss international issues, marking the partnership anniversary. Economic inspections reported.

2026 Investment Strategies: How Standard Chartered Korea Recommends Expanding U.S. and Asia Stock Holdings

Standard Chartered Korea recommends diversifying investments in U.S. and Asian stocks, EM bonds, and gold for the second half of 2026.

Disney’s ‘Snow White’ Teases Magic and Drama in First Official Stills

Disney's 2025 fantasy musical film 'Snow White' reveals new characters and visuals in its first press stills.

How Rejuran’s DOT® PN Technology is Revolutionizing Skin Regeneration in Europe

HealthHow Rejuran's DOT® PN Technology is Revolutionizing Skin Regeneration in Europe
/ Pharma Research
/ Pharma Research

PharmaResearch successfully concluded its Rejuran Regeneration Roadshow Paris at the Salomon de Rothschild Hotel in Paris, France, on September 24, the company announced on Friday.

The symposium, which coincided with the French Society of Aesthetic Medicine (SFME) conference, a major medical aesthetics event in France, drew over 250 key medical professionals, including plastic surgeons, dermatologists, and aesthetic medicine specialists.

The event highlighted PharmaResearch ‘s proprietary DOT® PN technology, along with the latest clinical data and practical applications of Rejuran.

Polynucleotide (PN) is a polymer composed of multiple nucleotides that make up DNA. PharmaResearch uses PN extracted and purified from salmon for various applications, including skin tissue regeneration.

In partnership with VIVACY, a global aesthetic company serving as its strategic distribution partner in Europe, PharmaResearch co-organizes academic roadshows in key European countries, including France. This strategy aims to rapidly expand academic connections with medical professionals through participation in major local conferences and specialized training programs.

Notably, the surge in product demand, driven by the clinical trust of local medical professionals, has led to supply shipments already exceeding initial plans by more than twofold. Consequently, PharmaResearch expects its annual supply performance in the European market to significantly surpass the original contractual volumes with its partners.

A PharmaResearch spokesperson stated that it has successfully communicated the clinical efficacy of Rejuran and the value of regenerative medicine to local medical professionals in France, the epicenter of European aesthetics. Through the partnership with VIVACY, it aims to establish ourselves as the leading brand in the European medical aesthetics market within the next three years.

Check Out Our Content

Check Out Other Tags:

Most Popular Articles